First Clinical Experience With the Incor Left Ventricular Assist Device
| Autor: | Tonny D.T. Tjan, Gabi Drees, Christof Schmid, Frauke Wenzelburger, Christian D. Etz, Hans H. Scheld, Markus J. Wilhelm, Christoph Schmidt, Markus Rothenburger |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
Adult
Male Pulmonary and Respiratory Medicine medicine.medical_specialty Heart disease medicine.medical_treatment law.invention Prosthesis Implantation Ventricular Dysfunction Left law Thromboembolism Artificial heart Internal medicine medicine.artery Ascending aorta medicine Humans Myocardial infarction Heart Failure Heart transplantation Transplantation L-Lactate Dehydrogenase business.industry Bilirubin Dilated cardiomyopathy Middle Aged Creatine medicine.disease Surgery Treatment Outcome Heart failure Ventricular assist device Cardiology Heart Transplantation Female Heart-Assist Devices Cardiology and Cardiovascular Medicine business |
| Zdroj: | The Journal of Heart and Lung Transplantation. 24:1188-1194 |
| ISSN: | 1053-2498 |
| DOI: | 10.1016/j.healun.2004.08.024 |
| Popis: | Background The Incor (Berlin Heart AG, Germany) is a small (200 g), implantable, magnetically accentuated axial flow pump (non-pulsatile flow) designed to support the left ventricle for extended periods of time. We report on the first single-center clinical experience with this device. Methods The Incor was studied in 15 consecutive patients (10 men, 5 women), 24 to 59 years of age. Underlying heart disease was end-stage ischemic heart disease ( n = 5), acute myocardial infarction ( n = 4), dilated cardiomyopathy ( n = 3), acute myocarditis ( n = 2) and Chagas disease ( n = 1). All patients were in New York Heart Association (NYHA) Class IV heart failure. Four patients had prior open heart surgery. Implantation via cannulation of the left ventricular apex and the ascending aorta was elective in 6 patients and on an emergency basis in 9. Results No early bleeding complications were seen, but late bleeding occurred in 4 patients. Minor cerebral thromboembolic events with transient neurologic symptoms occurred in 3 patients; severe stroke had to be treated in 1 patient. Systemic emboli were seen in 2 patients. Thrombus-related pump dysfunction was suspected in 3 patients, and managed by intensifying anti-coagulation. Five patients were successfully transplanted after a support interval of 90 to 156 days; 1 patient could be weaned from the system after 171 days. Six patients died during support, 9 to 63 days after device implantation. The remaining 3 patients are still under support, with excellent quality of life. Conclusions The Incor is a left ventricular assist device (LVAD) with transplant and adverse event rates comparable to those of other modern ventricular support devices. Its advantages include the small pump chamber, the virtual absence of device-related infections, and the extraordinary convenience during implantation and explantation. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|